Pomerantz Law Firm Warns Investors of Class Action Against ImmunityBio, Inc.
In a significant development for investors, Pomerantz LLP has announced a class action lawsuit against ImmunityBio, Inc. (NASDAQ: IBRX), a company known for its development of innovative therapies. The law firm is advising those who have suffered losses during their investment in ImmunityBio to come forward and join the legal action. Investors are encouraged to contact Danielle Peyton at Pomerantz directly to discuss their potential status in this case.
The allegations in the lawsuit revolve around securities fraud and other fraudulent business practices that may have involved some of ImmunityBio’s officers and directors. Specifically, the case is prompted by a public warning letter issued by the U.S. Food and Drug Administration (FDA) on March 13, 2026. The FDA's letter raised serious concerns regarding ImmunityBio’s marketing of its bladder cancer treatment, Anktiva, highlighting a pattern of misleading promotions despite earlier warnings. This has raised alarm among investors, particularly following a notable drop in the company’s stock price.
On March 24, following the FDA warning becoming public knowledge, ImmunityBio’s stock plummeted by $1.99, reflecting a decline of approximately 21.12%. This sharp decline is indicative of the market's reaction to the regulatory scrutiny and raises questions about the company's transparency and the accuracy of its promotional claims.
For those who acquired ImmunityBio securities during the relevant class period, there are critical deadlines looming. Investors must act quickly; they have until May 26, 2026, to apply for Lead Plaintiff status within this class action. Individuals interested in obtaining more details and a copy of the complaint can do so by visiting the Pomerantz Law Firm's official website.
Pomerantz LLP is a highly regarded law firm with a long-standing tradition of advocating for the rights of investors. With offices across the world, including New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, the firm has built its reputation on fighting against corporate misconduct, securities fraud, and breaches of fiduciary duty. Under the guidance of its founder, Abraham L. Pomerantz, often described as the dean of the class action bar, the firm has successfully recovered millions in damages for its clients.
As the financial fallout from ImmunityBio grows more apparent, this class action serves as a critical reminder for investors to remain vigilant about their rights and options in the face of troubling corporate conduct.
For additional inquiries, investors should reach out to Danielle Peyton via the contact details provided by Pomerantz LLP: email at [email protected] or by calling 646-581-9980, toll-free hotline at 888.4-POMLAW, ext. 7980. It's advisable for those contacting the firm to provide their mailing address, contact number, and the number of shares they purchased to expedite the process of joining the class action.
The Lawsuit Details
The allegations in the lawsuit revolve around securities fraud and other fraudulent business practices that may have involved some of ImmunityBio’s officers and directors. Specifically, the case is prompted by a public warning letter issued by the U.S. Food and Drug Administration (FDA) on March 13, 2026. The FDA's letter raised serious concerns regarding ImmunityBio’s marketing of its bladder cancer treatment, Anktiva, highlighting a pattern of misleading promotions despite earlier warnings. This has raised alarm among investors, particularly following a notable drop in the company’s stock price.
On March 24, following the FDA warning becoming public knowledge, ImmunityBio’s stock plummeted by $1.99, reflecting a decline of approximately 21.12%. This sharp decline is indicative of the market's reaction to the regulatory scrutiny and raises questions about the company's transparency and the accuracy of its promotional claims.
Important Deadlines and Next Steps
For those who acquired ImmunityBio securities during the relevant class period, there are critical deadlines looming. Investors must act quickly; they have until May 26, 2026, to apply for Lead Plaintiff status within this class action. Individuals interested in obtaining more details and a copy of the complaint can do so by visiting the Pomerantz Law Firm's official website.
About Pomerantz LLP
Pomerantz LLP is a highly regarded law firm with a long-standing tradition of advocating for the rights of investors. With offices across the world, including New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, the firm has built its reputation on fighting against corporate misconduct, securities fraud, and breaches of fiduciary duty. Under the guidance of its founder, Abraham L. Pomerantz, often described as the dean of the class action bar, the firm has successfully recovered millions in damages for its clients.
As the financial fallout from ImmunityBio grows more apparent, this class action serves as a critical reminder for investors to remain vigilant about their rights and options in the face of troubling corporate conduct.
For additional inquiries, investors should reach out to Danielle Peyton via the contact details provided by Pomerantz LLP: email at [email protected] or by calling 646-581-9980, toll-free hotline at 888.4-POMLAW, ext. 7980. It's advisable for those contacting the firm to provide their mailing address, contact number, and the number of shares they purchased to expedite the process of joining the class action.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.